Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
VolitionRx Limited is a life sciences company focused on the development and commercialization of blood-based diagnostic tests that leverage its proprietary Nu.Q® nucleosome technology. The company operates within the diagnostics and biotechnology industries, with a particular emphasis on early disease detection through minimally invasive testing. Its core value proposition is the ability to identify disease-associated changes in circulating nucleosomes, which are released into the bloodstream during cell death, enabling earlier and potentially more accurate detection than conventional methods.
The company’s primary revenue drivers are research-use-only diagnostic products, development collaborations, and licensing arrangements, with long-term objectives centered on regulated clinical diagnostics. VolitionRx serves clinical laboratories, researchers, veterinarians, and pharmaceutical partners, with applications spanning oncology, infectious disease, organ transplant monitoring, and veterinary diagnostics. Founded in 2007, the company evolved from an early-stage research entity into a publicly traded diagnostics developer, completing its transition to a Nevada-incorporated holding company listed on the NYSE American under the ticker VNRX.
Business Operations
VolitionRx operates through several business units aligned with the application of its Nu.Q® technology, including Nu.Q® Discover, Nu.Q® Vet, and Nu.Q® Dx. These segments encompass research-use immunoassays, veterinary cancer screening tests, and clinical diagnostic development programs. Revenue is generated through kit sales, licensing fees, milestone payments, and strategic collaborations, while significant resources are allocated to research, validation studies, and regulatory preparation.
The company maintains intellectual property covering nucleosome-based biomarkers and assay methods, supported by laboratory and development facilities primarily in Europe and the United States. Its operations include wholly owned subsidiaries such as Volition Diagnostics UK Limited and Volition America, Inc., which support R&D, regulatory strategy, and commercialization. VolitionRx has also entered into partnerships with academic institutions, veterinary distributors, and diagnostic companies to expand validation efforts and market reach.
Strategic Position & Investments
VolitionRx’s strategic direction centers on expanding the clinical and commercial adoption of Nu.Q® assays, with a near-term focus on veterinary oncology as a revenue-generating market and a longer-term focus on regulated human diagnostics. Growth initiatives include broadening assay menus, conducting large-scale clinical studies, and pursuing regulatory pathways in multiple jurisdictions. The company has emphasized capital-efficient development through partnerships rather than large-scale acquisitions.
Notable investments include sustained funding of its European research operations and the advancement of proprietary assay platforms designed to integrate into existing laboratory workflows. VolitionRx is also engaged in emerging areas such as multi-cancer early detection and treatment response monitoring, positioning its technology as complementary to imaging and genomic diagnostics rather than a direct replacement.
Geographic Footprint
VolitionRx is headquartered in the United States, with operational and research centers in Europe, particularly Belgium and the United Kingdom. These regions support assay development, clinical research, and intellectual property management. The company’s structure reflects its origins in European research while maintaining access to U.S. capital markets and regulatory frameworks.
Commercial and research collaborations extend across North America, Europe, and parts of Asia, especially in veterinary diagnostics distribution. While the majority of revenues to date are generated from international research and veterinary markets, the company continues to build infrastructure to support broader global commercialization as regulatory approvals are pursued.
Leadership & Governance
VolitionRx is led by a management team with experience in diagnostics, life sciences, and public company governance. The leadership philosophy emphasizes scientific validation, disciplined capital allocation, and partnership-driven growth, with strategic oversight provided by a board that includes executives with backgrounds in biotechnology commercialization and finance.
Key executives include:
- Cameron Reynolds – President and Chief Executive Officer
- Guy Archibald – Chief Financial Officer
- Dr. Jake Micallef – Chief Scientific Officer
- Ian Pike – Chief Operating Officer
- Andrew Retter – Non-Executive Chairman of the Board
The company operates under standard public-company governance practices, with oversight informed by regulatory requirements and shareholder interests, and strategic decisions aligned with long-term diagnostic market opportunities.